(Corrects after European Commission says 37 signatories not 36)
BRUSSELS, Oct 8 (Reuters) - The European Commission said on
Thursday it had signed a contract with U.S. drugmaker Gilead
for the supply of up to 500,000 treatment courses for
remdesivir, sharply increasing the supply of the COVID-19
treatment in Europe.
The Commission, which has overseen joint purchases of
vaccines in the European Union, said there were 37 signatories
to the agreement, including all EU countries, six Balkan
candidate and potential EU members, Britain and the other
European Economic Area countries Iceland, Liechtenstein and
Norway.
(Reporting by Marine Strauss and Philip Blenkinsop; Editing by
Edmund Blair)